title: Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
abstract: OBJECTIVE
  Epidermal growth factor receptor inhibitor (EGFRi) therapy for tumor suppression produces significant cutaneous toxicity that may necessitate dose reduction or treatment cessation. This manuscript aims to describe the skin toxicity associated with these agents and equip oncologists with the tools to best manage these patients.
  
  
  METHODS
  A literature review of skin toxicity associated with EGFRi was conducted by a clinical dermatologist experienced in the management of these patients and a management strategy developed for EGFRi skin toxicity
  
  
  RESULTS
  The sequence of development of EGFRi cutaneous toxicity is predictable. Many skin side effects can be ameliorated by prophylactic therapy. Management of established skin toxicity is complex and needs to be continued throughout the period of EGFRi drug treatment.
  
  
  CONCLUSIONS
  Early referral to a dermatologist experienced in the management of these patients is recommended.
authors: Epworth Hospital, Melbourne, Victoria, Australia; University of Melbourne, Melbourne, Victoria, Australia.
authors: Rod
authors: R
authors: Sinclair
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D012867:Skin / Q000187:drug effects* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGF receptor inhibitor; MASCC; cetuximab; drug-induced rash; guideline